ClearPoint Neuro Entered into a Multi-Year License Agreement with UCB for Gene Therapy Drug Delivery
- ClearPoint Neuro is eligible to receive success-based milestones. The companies’ focus is to develop drug delivery platforms for Belgian biopharma’s gene therapy portfolio
- The agreement enables UCB to use ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products. The agreement also advances UCB’s research and development pipeline in gene therapy
- Additionally, ClearPoint Neuro Navigation System received the US FDA clearance, was CE-marked, and was installed in ~65 active sites in North America, the EU, and South America
Ref: ClearPoint Neuro | Image: ClearPoint Neuro
Related News:- Opus Genetics Acquires Two Gene Therapy Candidates from Iveric Bio for the Treatment of Inherited Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].